Arrowhead Pharmaceuticals, Inc.
US ˙ NasdaqGS ˙ US04280A1007

SecurityARWR / Arrowhead Pharmaceuticals, Inc.
InstitutionFifth Third Bancorp
Latest Disclosed Ownership33,447 shares
Latest Disclosed Value $ 2,097,088
Fifth Third Bancorp reports 2,648.32% increase in ownership of ARWR / Arrowhead Pharmaceuticals, Inc.

On May 1, 2026 - Fifth Third Bancorp filed a 13F-HR form disclosing ownership of 33,447 shares of Arrowhead Pharmaceuticals, Inc. (US:ARWR) valued at $2,097,127 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 2, 2026 disclosing 1,217 shares of Arrowhead Pharmaceuticals, Inc.. This represents a change in shares of 2,648.32% during the quarter. The current value of the position is $2,426,580 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-01 2026-03-31 13F ARROWHEAD PHARMACEUTICALS IN COM 04280A100 33,447 32,230 2,648.32 2,097 2,521.25 0.0038
2026-02-02 2025-12-31 13F ARROWHEAD PHARMACEUTICALS IN COM 04280A100 1,217 67 5.83 81 105.13 0.0003
2025-11-07 2025-09-30 13F ARROWHEAD PHARMACEUTICALS IN COM 04280A100 1,150 -215 -15.75 40 85.71 0.0001
2025-07-15 2025-06-30 13F ARROWHEAD PHARMACEUTICALS IN COM 04280A100 1,365 894 189.81 22 250.00 0.0001
2025-04-15 2025-03-31 13F ARROWHEAD PHARMACEUTICALS IN COM 04280A100 471 -899 -65.62 6 -76.00 0.0000
2025-01-21 2024-12-31 13F ARROWHEAD PHARMACEUTICALS IN COM 04280A100 1,370 53 4.02 26 0.00 0.0001
2024-10-17 2024-09-30 13F ARROWHEAD PHARMACEUTICALS IN COM 04280A100 1,317 131 11.05 26 -16.67 0.0001
2024-07-22 2024-06-30 13F ARROWHEAD PHARMACEUTICALS IN COM 04280A100 1,186 354 42.55 31 30.43 0.0001
2024-04-23 2024-03-31 13F ARROWHEAD PHARMACEUTICALS IN COM 04280A100 832 -330 -28.40 24 -34.29 0.0001
2024-01-19 2023-12-31 13F ARROWHEAD PHARMACEUTICALS IN COM 04280A100 1,162 174 17.61 36 34.62 0.0002
2023-10-31 2023-09-30 13F ARROWHEAD PHARMACEUTICALS IN COM 04280A100 988 522 112.02 27 62.50 0.0001
2023-07-26 2023-06-30 13F ARROWHEAD PHARMACEUTICALS IN COM 04280A100 466 326 232.86 17 433.33 0.0001
2023-04-24 2023-03-31 13F ARROWHEAD PHARMACEUTICALS IN COM 04280A100 140 -203 -59.18 4 -76.92 0.0000
2023-01-25 2022-12-31 13F ARROWHEAD PHARMACEUTICALS IN COM 04280A100 343 -75 -17.94 14 -7.14 0.0001
2022-10-25 2022-09-30 13F ARROWHEAD PHARMACEUTICALS IN COM 04280A100 418 -135 -24.41 14 -26.32 0.0001
2022-08-04 2022-06-30 13F ARROWHEAD PHARMACEUTICALS IN COM 04280A100 553 338 157.21 19 90.00 0.0001
2022-04-19 2022-03-31 13F ARROWHEAD PHARMACEUTICALS IN COM 04280A100 215 -222 -50.80 10 -65.52 0.0000
2022-02-01 2021-12-31 13F ARROWHEAD PHARMACEUTICALS IN COM 04280A100 437 131 42.81 29 52.63 0.0001
2021-10-15 2021-09-30 13F ARROWHEAD PHARMACEUTICALS IN COM 04280A100 306 136 80.00 19 35.71 0.0001
2021-08-06 2021-06-30 13F ARROWHEAD PHARMACEUTICALS IN COM 04280A100 170 40 30.77 14 55.56 0.0001
2021-05-07 2021-03-31 13F ARROWHEAD PHARMACEUTICALS IN COM 04280A100 130 -5 -3.70 9 -10.00 0.0000
2021-02-16 2020-12-31 13F ARROWHEAD PHARMACEUTICALS IN COM 04280A100 135 110 440.00 10 900.00 0.0000
2020-11-09 2020-09-30 13F ARROWHEAD PHARMACEUTICALS IN COM 04280A100 25 25 1 0.0000
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.